Ascendis Pharma (ASND) Prices 2M Share Offering at $150/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
September 23, 2024 5:11 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $191.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "We hosted an expert pediatric endocrinologist to discuss his views on ASNDs TransCon CNP in achondroplasia (ACH) following the recent topline ph 3 readout (see our Sep 16th note). Overall, our KOL was encouraged by the stat sig AGV... More
